FDA Sparks Hope for Curis, Lets Biotech Resume Enrollment for Part of Phase I/II Leukemia Study

Curis has received another spark of hope as the FDA lets the biotech resume enrollment for a part of its Phase I/II study assessing emavusertib in patients with leukemia.